Sandra Abrevaya

May 27, 2024 | joethemnmovieman.com | Brian Wallach |Christopher Burke |Sandra Abrevaya

Synopsis: One couple’s fight to reclaim their future from a brutal disease has snowballed into a movement with resounding ramifications for the ALS community and millions of patients seeking a voice in our broken healthcare system.

Apr 19, 2023 | synapticure.com | Sandra Abrevaya

Synapticure proudly announces our recently IRB-approved study that focuses on presymptomatic individuals who carry a pathogenic or likely-pathogenic gene variant of ALS. Participants in this study will be given the option to take Riluzole, one of the FDA-approved treatments for ALS. There is no placebo for this study, so all eligible participants will receive the medication. Who is eligible?